The Natural Flavone Acacetin Blocks Small Conductance Ca2+-Activated K+ Channels Stably Expressed in HEK 293 Cells

The natural flavone acacetin inhibits several voltage-gated potassium currents in atrial myocytes, and has anti-atrial fibrillation (AF) effect in experimental AF models. The present study investigates whether acacetin inhibits the Ca²⁺-activated potassium (K_Ca) currents, including small conductance (SK_Ca1, SK_Ca2, and SK_Ca3), intermediate conductance (IK_Ca), and large-conductance (BK_Ca) channels stably expressed in HEK 293 cells. The effects of acacetin on these K_Ca channels were determined with a whole-cell patch voltage-clamp technique. The results showed that acacetin inhibited the three subtype SK_Ca channel currents in concentration-dependent manner with IC₅₀ of 12.4 μM for SK_Ca1, 10.8 μM for SK_Ca2, and 11.6 μM for SK_Ca3. Site-directed mutagenesis of SK_Ca3 channels generated the mutants H490N, S512T, H521N, and A537V. Acacetin inhibited the mutants with IC₅₀ of 118.5 μM for H490N, 275.2 μM for S512T, 15.3 μM for H521N, and 10.6 μM for A537V, suggesting that acacetin interacts with the P-loop helix of SK_Ca3 channel. However, acacetin at 3–10 μM did not decrease, but induced a slight increase of BK_Ca (+70 mV) by 8% at 30 μM. These results demonstrate the novel information that acacetin remarkably inhibits SK_Ca channels, but not IK_Ca or BK_Ca channels, which suggests that blockade of SK_Ca by acacetin likely contributes to its anti-AF property previously observed in experimental AF.

Increasing small conductance Ca2+-activated potassium channel activity reverses ischemia-induced impairment of long-term potentiation

Global cerebral ischemia following cardiac arrest and cardiopulmonary resuscitation (CA/CPR) causes injury to hippocampal CA1 pyramidal neurons and impairs cognition. Small conductance Ca(2+)-activated potassium channels type 2 (SK2), expressed in CA1 pyramidal neurons, have been implicated as potential protective targets. Here we showed that, in mice, hippocampal long-term potentiation (LTP) was impaired as early as 3 h after recovery from CA/CPR and LTP remained impaired for at least 30 days. Treatment with the SK2 channel agonist 1-Ethyl-2-benzimidazolinone (1-EBIO) at 30 min after CA provided sustained protection from plasticity deficits, with LTP being maintained at control levels at 30 days after recovery from CA/CPR. Minimal changes in glutamate release probability were observed at delayed times after CA/CPR, implicating post-synaptic mechanisms. Real-time quantitative reverse transcriptase-polymerase chain reaction indicated that CA/CPR did not cause a loss of N-methyl-D-aspartate (NMDA) receptor mRNA at 7 or 30 days after CA/CPR. Similarly, no change in synaptic NMDA receptor protein levels was observed at 7 or 30 days after CA/CPR. Further, patch-clamp experiments demonstrated no change in functional synaptic NMDA receptors at 7 or 30 days after CA/CPR. Electrophysiology recordings showed that synaptic SK channel activity was reduced for the duration of experiments performed (up to 30 days) and that, surprisingly, treatment with 1-EBIO did not prevent the CA/CPR-induced loss of synaptic SK channel function. We concluded that CA/CPR caused alterations in post-synaptic signaling that were prevented by treatment with the SK2 agonist 1-EBIO, indicating that activators of SK2 channels may be useful therapeutic agents to prevent ischemic injury and cognitive impairments.